晚期前列腺癌间歇性与连续性雄激素剥夺治疗的严重毒性风险:一项基于人群的研究
该研究纳入2002至2011年诊断的9772例66岁及以上晚期前列腺癌患者,比较间歇性与连续性雄激素剥夺治疗的严重毒性风险。结果显示,与连续治疗组相比,间歇治疗组严重心血管事件风险更低(HR 0.64,95%CI 0.53-0.77),其中心力衰竭(HR 0.62,95%CI 0.49-0.78)和骨折(HR 0.52,95%CI 0.38-0.70)风险均更低,各p<0.0001。作者认为间歇治疗可能是老年晚期前列腺癌患者更安全的选择。
要点
- 与连续雄激素剥夺治疗相比,间歇治疗组严重心血管事件风险更低(HR 0.64,95%CI 0.53-0.77)。
- 间歇治疗组心力衰竭风险更低(HR 0.62,95%CI 0.49-0.78,p<0.0001)。
- 间歇治疗组骨折风险更低(HR 0.52,95%CI 0.38-0.70,p<0.0001)。
核心结论
- 与连续性雄激素剥夺治疗相比,间歇性雄激素剥夺治疗与更低的心力衰竭和骨折风险相关。
- 作者认为间歇性雄激素剥夺治疗可能是老年晚期前列腺癌患者更安全的治疗选择。
研究设计与样本
- 基于人群的队列研究,纳入9772例66岁及以上、2002至2011年诊断并接受雄激素剥夺治疗的晚期前列腺癌男性患者。
- 间歇性雄激素剥夺治疗定义为两次雄激素剥夺治疗会话之间仅有单个90天间隔,期间患者就诊或接受前列腺特异性抗原检测。
- 采用Cox比例风险模型估计间歇性与连续性雄激素剥夺治疗之间严重毒性的比较风险HR。
主要发现
- 开始雄激素剥夺治疗后5年内,2113例(22%)发生新发心血管事件,769例(9%)发生糖尿病,899例(9%)发生骨折。
- 与连续治疗组相比,间歇治疗组严重心血管事件风险更低(HR 0.64,95%CI 0.53-0.77)。
- 与连续治疗组相比,间歇治疗组心力衰竭风险更低(HR 0.62,95%CI 0.49-0.78,p<0.0001)。
- 与连续治疗组相比,间歇治疗组骨折风险更低(HR 0.52,95%CI 0.38-0.70,p<0.0001)。
临床怎么用
- 作者认为间歇性雄激素剥夺治疗可能是老年晚期前列腺癌患者更安全的治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Randomized trials have shown that intermittent androgen deprivation therapy for patients with advanced prostate cancer may improve sexual and physical functioning compared to continuous androgen deprivation therapy without compromising survival. To our knowledge it is unknown whether intermittent androgen deprivation therapy alters the risk of serious toxicities associated with continuous androgen deprivation therapy. MATERIALS AND METHODS: We performed a population based cohort study of 9,772 men 66 years old or older who were diagnosed with advanced prostate cancer from 2002 to 2011 and treated with androgen deprivation therapy. Intermittent androgen deprivation therapy was defined as a single 90-day interval between 2 androgen deprivation therapy sessions during which patients visited their physicians or underwent prostate specific antigen testing. Outcomes included acute myocardial infarction, stroke, heart failure, type 2 diabetes and fracture. We used Cox proportional hazard models to estimate the HRs of the comparative risk of serious toxicities between intermittent and continuous androgen deprivation therapy. RESULTS: A total of 2,113 (22%), 769 (9%) and 899 men (9%) had a new cardiovascular event, diabetes or fracture, respectively, within 5 years of starting androgen deprivation therapy. Compared to the continuous androgen deprivation therapy group, the intermittent therapy group was at lower risk for serious cardiovascular events (HR 0.64, 95% CI 0.53-0.77), particularly in reducing the risk of heart failure (HR 0.62, 95% CI 0.49-0.78) and fracture (HR 0.52, 95% CI 0.38-0.70, each p <0.0001). CONCLUSIONS: Intermittent androgen deprivation therapy was associated with a lower risk of heart failure and fracture compared to continuous androgen deprivation therapy. This raises toxicity concerns for continuous relative to intermittent therapy and suggests that intermittent androgen deprivation therapy may represent a safer therapeutic choice in elderly men with advanced prostate cancer.
引用
- Tsai HT, Pfeiffer RM, Philips GK, et al. Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. J Urol. 2016. PMID: 27993663. doi:10.1016/j.juro.2016.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。